Bluebird Bio, Inc. (BLUE)
| Market Cap | 1.92B |
| Revenue (ttm) | 250.73M |
| Net Income (ttm) | -618.70M |
| Shares Out | 62.18M |
| EPS (ttm) | -9.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 8 |
| Last Price | $28.25 |
| Previous Close | $28.68 |
| Change ($) | -0.43 |
| Change (%) | -1.50% |
| Day's Open | 28.86 |
| Day's Range | 28.19 - 29.66 |
| Day's Volume | 1,037,469 |
| 52-Week Range | 24.24 - 72.51 |
New York, New York--(Newsfile Corp. - March 8, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) ...
NEW YORK--(BUSINESS WIRE)---- $BLUE--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on be...
New York, New York--(Newsfile Corp. - March 8, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between...
New York, New York--(Newsfile Corp. - March 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securiti...
New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE...
New York, New York--(Newsfile Corp. - March 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securiti...
NEW YORK, March 06, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline for investors to file a lead plaintiff motio...
New York, New York--(Newsfile Corp. - March 5, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) ...
Philadelphia, Pennsylvania--(Newsfile Corp. - March 5, 2021) - Berger Montague is investigating potential securities fraud claims against bluebird bio, Inc. ("bluebird" or the "Company") on b...
New York, New York--(Newsfile Corp. - March 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securiti...
LOS ANGELES, March 4, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against bluebird bio, Inc. ("blueb...
New York, New York--(Newsfile Corp. - March 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securiti...
NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, 2...
LEAD PLAINTIFF DEADLINE IS APRIL 13, 2021 LEAD PLAINTIFF DEADLINE IS APRIL 13, 2021
New York, New York--(Newsfile Corp. - March 2, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) ...
NEW YORK, March 1, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, 2020 a...
New York, New York--(Newsfile Corp. - March 1, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securiti...
NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline for investors to file a lead plaintiff motio...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, 2020 and November 4...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Cowen 41st Annual Health Care Conference, Wedne...
New York, New York--(Newsfile Corp. - February 25, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BL...
New York, New York--(Newsfile Corp. - February 24, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secu...
NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of bluebird bio, Inc. (Nasdaq: BLUE) and Bristol Myers Squibb's (NYSE: BMY) ...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BL...
bluebird (BLUE) reports a narrower-than-expected loss but misses sales estimates in the fourth quarter of 2020.
NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline for investors to file a lead plaintiff motion...
LOS ANGELES--(BUSINESS WIRE)---- $BLUE #CLASSACTION--Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BL...
NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of bluebird bio, Inc. (NASDAQ: BLUE) from May 11, 20...
Investors are ditching this gene therapy stock en masse, for good reason.
New York, New York--(Newsfile Corp. - February 23, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of th...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ:BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and sh...
Los Angeles, California--(Newsfile Corp. - February 23, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against blue...
BENSALEM, Pa.--(BUSINESS WIRE)---- $BLUE #CLASSACTION--Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio,...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the 10th Annual SVB Leerink Global Healthcare Confe...
New York, New York--(Newsfile Corp. - February 22, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secu...
New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: ...
LOS ANGELES--(BUSINESS WIRE)---- $BLUE #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of BLUE Inves...
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of bluebird bio, Inc. (NASDAQ:BLUE) between May 11, ...
New York, New York--(Newsfile Corp. - February 19, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: B...
BENSALEM, Pa.--(BUSINESS WIRE)---- $BLUE #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) I...
LOS ANGELES--(BUSINESS WIRE)---- $BLUE #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) Investors
NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a announces that a federal securities class action lawsuit has been filed in the United States ...
PHILADELPHIA, Feb. 19, 2021 /PRNewswire/ -- Berger Montague is investigating potential securities fraud claims against bluebird bio, Inc. ("bluebird" or the "Company") on behalf of investors w...
NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and certain o...
New York, New York--(Newsfile Corp. - February 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secu...
NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ...
Los Angeles, California--(Newsfile Corp. - February 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against blueb...
New York, New York--(Newsfile Corp. - February 18, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BL...
About BLUE
bluebird bio, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) ... [Read more...]
| Industry Biotechnology | IPO Date Jun 19, 2013 |
| CEO Nick Leschly | Employees 1,201 |
| Stock Exchange NASDAQ | Ticker Symbol BLUE |
Financial Performance
In 2020, Bluebird Bio's revenue was $250.73 million, an increase of 461.25% compared to the previous year's $44.67 million. Losses were -$618.70 million, -21.65% less than in 2019.
Analyst Forecasts
According to 24 analysts, the average rating for Bluebird Bio stock is "Buy." The 12-month stock price forecast is 46.53, which is an increase of 64.71% from the latest price.